NCT04985357 2024-11-25Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsTravera IncWithdrawn
NCT00499291 2023-05-25Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid TumorsEastern Cooperative Oncology GroupPhase NA Withdrawn
NCT00458315 2015-05-08Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary TumorRigshospitalet, DenmarkPhase 2 Withdrawn